Evidence mapPaperPMID 40710508Full record

ReviewMarine drugs2025

Marine-Derived Compounds: A New Horizon in Cancer, Renal, and Metabolic Disease Therapeutics.

Jinwei Zhang

Abstract readReview
In one paragraph

Review in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jinwei ZhangInstitute of Biomedical and Clinical Sciences, Medical School, Faculty of Health and Life Sciences, Hatherly Laboratories, Streatham Campus, University of Exeter, Exeter EX4 4PS, UK.ORCID 0000-0001-8683-509X

Funding

The Royal Society UK IEC\NSFC\201094
6 · The paper itself

Abstract

Marine-derived compounds represent a rich source of structurally diverse molecules with therapeutic potential for cancer, renal disorders, metabolic-associated fatty liver disease (MAFLD), and atherosclerosis. This review systematically evaluates recent advances, highlighting compounds such as Microcolin H, Benzosceptrin C, S14, HN-001, Equisetin, glycosides (e.g., cucumarioside A

Indexed as

Antineoplastic AgentsAquatic OrganismsBiological ProductsKidney DiseasesMetabolic DiseasesNeoplasmsAnimalsDrug DevelopmentHumansStructure-Activity RelationshipAntineoplastic AgentsBiological Productsautophagycancer therapyimmune checkpoint inhibitorskinase inhibitorsmarine-derived compoundsmetabolic-associated fatty liver diseasepharmacokineticsPRISMArenal diseasestructure–activity relationship

Identifiers

PMID40710508
PMCPMC12300890

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.